X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CordenPharma will Provide manufacturing support for Revolo Bio’s first-in-class peptide and immune system resetting drug product, ‘1104, for its upcoming Phase 2 clinical trials in patients with eosinophilic esophagitis (EoE) and allergic disease.
Lead Product(s): IRL201104
Therapeutic Area: Gastroenterology Product Name: ‘1104
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Revolo Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 15, 2021
Details:
The amended agreement now includes CordenPharma Chenôve (FR) and CordenPharma Colorado (US) for the manufacture of larger-scale volumes of lipids, while continuing to draw upon CordenPharma Switzerland’s long-standing reputation as a leader in specialized lipid manufacturing.
Lead Product(s): mRNA-1273
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
